Additionally, in anti-TIGIT antibody-treated spleens, there were more NK (CD3e–NK1.1+NKp46+) cells within the CD45.1+ tumor immune environment and concomitantly greater NK cell activation (as indicated by granzyme B expression) following anti-TIGIT treatment (Supplemental Figure 12, J and K). The gene discussed is NCR1; the disease is neoplasm.